53342-23-7

Basic information

• Product Name: Benzyl Morpholinoacetate
• Synonyms: Benzyl Morpholinoacetate;Morpholin-4-yl-acetic acid benzyl ester;4-Morpholineacetic acid phenylmethyl ester;benzyl 2-morpholinoacetate
• CAS NO: 53342-23-7
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235
• Mol File: 53342-23-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 344.112°C at 760 mmHg
• Flash Point: 161.914°C
• Appearance: /
• Density: 1.138g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.53
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzyl Morpholinoacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl Morpholinoacetate(53342-23-7)
• EPA Substance Registry System: Benzyl Morpholinoacetate(53342-23-7)

Safety Data

• Hazardous Substances Data: 53342-23-7(Hazardous Substances Data)

Usage

General Description

Benzyl morpholinoacetate is a chemical compound with the molecular formula C13H17NO3. It is a benzyl ester of morpholinoacetic acid, and is commonly used as a reagent in organic synthesis. Benzyl Morpholinoacetate has been studied for its potential use as a chiral auxiliary in asymmetric synthesis, as well as its role in the formation of benzyl morpholinoacetate-based materials with potential applications in drug delivery and tissue engineering. Additionally, benzyl morpholinoacetate has been investigated for its anti-inflammatory and antinociceptive properties, making it a compound of interest in the development of new pharmaceuticals.

InChI:InChI=1/C13H17NO3/c15-13(10-14-6-8-16-9-7-14)17-11-12-4-2-1-3-5-12/h1-5H,6-11H2

Upstream product

• 100-51-6 benzyl alcohol 
• 110-91-8 morpholine 
• 5437-45-6 Benzyl bromoacetate 
• 140-18-1 Benzyl chloroacetate 

Downstream Products

• 3235-69-6 morpholin-4-ylacetic acid 

Relevant articles and documents

MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES

Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol

The structure-activity relationships in two series of novel, symmetry-based inhibitors of HIV protease, the enzyme responsible for maturation of the human immunodeficiency virus, are described.Beginning with lead compounds 3-6, the effect of adding polar, heterocyclic end groups to one or both ends of the symmetric or pseudosymmetric inhibitors was probed.Aqueous solubility was enhanced >1000-fold while maintaining potent inhibition of purified HIV-1 protease and anti-HIV activity in vitro.Pharmacokinetic studies in rats indicated a substantial difference in the absorption properties of mono-ol-based and diol-based inhibitors.The oral bioavailability of inhibitor 19 in rats was 19percent; however, the Cmax obtained failed to exceed the anti-HIV EC50 in vitro.Substantial plasma levels of potent inhibitors of the diol class were not obtained after oral administration in rats; however, the optimal combination of aqueous solubility and in vitro antiviral activity of several inhibitors support their potential use in intravenous therapy.